Summary
The effects of 6 weeks of treatment with dilevalol 100 mg once daily, or carteolol 10 mg once daily, on renal blood flow (RBF), glomerular filtration rate (GFR) and total renal vascular resistance (TRR) were studied in 10 patients with mild-to-moderate essential hypertension in a randomised cross-over experiment.
Both drugs lowered the systolic and diastolic blood pressures to a similar extent without altering the heart rate. Carteolol non-significantly decreased RBF by 9.2% and GFR by 12.3% without altering. TRR, whereas dilevalol produced a significant reduction in TRR by 13.2% (p<0.05), a non-significant decrease in RBF by 4.6% and no change in GFR.
Neither drug changed plasma osmotic pressure, serum total protein concentration, electrolytes or plasma aldosterone concentration. Plasma renin activity tended to be lower in the dilevalol phase as compared to the carteolol phase.
The results suggest that dilevalol may cause a greater decrease in TRR and less reduction in GFR when compared to carteolol in patients with mild-to-moderate essential hypertension. The difference in the renal effects might be due to the difference in the potency of vasodilatory properties of both drugs at the doses applied.
This is a preview of subscription content, log in via an institution to check access.
References
Bauer JH, Brooks CS (1979) The long term effect of propranolol therapy on renal function. Am J Med 66: 405–410
Warren SE, O'Connor DT, Cohen IM, Mitas JA (1981) Renal hemodynamic changes during long-term antihypertensive therapy. Clin Pharmacol Ther 29: 310–317
Wilkinson R, Stevens IM, Pickering M, Robson V, Hawkins T, Kerr DN, Harry JD (1980) A study of the effects of atenolol and propranolol on renal function in patients with essential hypertension. Br J Clin Pharmacol 10: 51–59
Wainer E, Boner G, Rosenfeld JB (1980) Effects of pindolol on renal function. Clin Pharmacol Ther 28: 575–580
Boner G, Wainer E, Rosenfeld JB (1982) Effects of pindolol on renal function. II. Effects of intravenous and prolonged oral dosing. Clin Pharmacol Ther 32: 423–427
Malini PL, Strocchi E, Negroni S, Ambrosioni E, Magnani B (1982) Renal haemodynamics after chronic treatment with labetalol and propranolol. Br J Clin Pharmacol 13 [Suppl 1]: 123S-126S
Larsen JS, Pedersen EB (1980) Comparison of the effects of propranolol and labetalol on renal haemodynamics at rest and during exercise in essential hypertension. Eur J Clin Pharmacol 18: 135–139
Sybertz EJ, Sabin DX, Pula KK, Vliet GV, Glennon J, Gold EH, Baum T (1981) Alpha-beta-adrenoceptor blocking properties of labetalol and its R,R-isomer, SCH 19927. J Pharmacol Exp Ther 218: 435–443
Baum T, Watkins RW, Sybertz EJ, Bemulapalli S, Pula KK, Eynon E, Nelson S, Bliet GV, Glennon J, Moran RM (1981) Antihypertensive and hemodynamic actions of SCH 19927, the R,R-isomer of labetalol. J Pharmacol Exp Ther 218: 444–452
Baba T, Murabayashi S, Aoyagi K, Ishizaki T (1988) Effects of dilevalol, R,R-isomer of labetalol, on blood pressure and renal function in patients with mild-to-moderate essential hypertension. Eur J Clin Pharmacol 35: 9–15
Yabuuchi Y, Kinoshita D (1974) Cardiovascular studies of 5-(3-tert-butylamino-2-hydroxypropoxy)-3,4-dihydrocarbostyril hydrochloride (OPC-1085), a new potent β-adrenergic blocking agent. Jpn J Pharmacol 24: 853–861
Hiramori N, Ishimori T, Taira N (1979) A further study on anti-hypertensive action of β-adrenoceptor blocking agents in conscious, renal hypertensive dogs. Arch Int Pharmacodyn Ther 242: 115–127
Ishizaki T, Ohnishi A, Sasaki T, Chiba K, Suganuma T, Kushida K (1983) Pharmacokinetics and absolute bioavailability of carteolol, a new β-adrenertic blocking agent. Eur J Clin Pharmacol 25: 95–101
Tabei K, Furuya H, Asano Y, Hosoda S (1989) Effect of carteolol on renal function in healthy subjects and patients with hypertension. Eur J Clin Pharmacol 36: 83–86
Baba T, Boku A, Ishizaki T, Sonne K, Takebe K (1986) Renal effects of nicardipine in patients with mild-to-moderate essential hypertension. Am Heart J 111: 552–557
Gomez DM (1951) Evaluation of renal resistance with specific reference to change in essential hypertension. J Clin Invest 30: 1143–1155
Haber E, Koerner T, Page LB, Klinman B, Purnode A (1969) Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 29: 1349–1355
Ogihara T, Iinuma K, Nishi K, Arakawa Y, Takagi A, Kurata K, Miyai K, Kumahara Y (1977) A non-chromatographic non-extraction radioimmunoassay for serum aldosterone. J Clin Endocrinol Metab 45: 726–731
Mercier DE, Feld RD, Witte DL (1978) Comparison of dewpoint and freezing point osmometry. Am J Med Technol 44: 1066–1069
Cook ME, Clifton GG, Poland MP, Flamenbaum W, Wallin JD (1986) Effects of dilevalol and atenolol on renal function and haemodynamics of patients with mild to moderate hypertension. J Hypertens 4: S504-S506
Tsukiyama H, Otsuka K, Higuma K (1982) Effect of β-adrenoceptor antagonists on central haemodynamics in essential hypertension. Br J Clin Pharmacol 13 [Suppl 2]: 269S-278S
O'Connor DT, Preston RA (1982) Urinary kallikrein activity, renal hemodynamics, and electrolyte handling during chronic beta blockade with propranolol in hypertension. Hypertension 4: 742–749
Textor SC, Fouad FM, Bravo EL, Tarazi RC, Vidt DG, Gifford RW (1982) Redistribution of cardiac output to the kidneys during oral nadolol administration. N Engl J Med 307: 602–605
Pedersen EB, Kornerup HJ (1976) Renal hemodynamics and plasma renin in patients with essential hypertension. Clin Sci Mol Med 50: 409–414
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baba, T., Murabayashi, S., Tomiyama, T. et al. Comparison of the renal effects of dilevalol and carteolol in patients with mild to moderate essential hypertension. Eur J Clin Pharmacol 38, 305–307 (1990). https://doi.org/10.1007/BF00315037
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315037